HK3 Antibody

What are the key technical specifications to consider when selecting an HK3 antibody for research?

When selecting an HK3 antibody for research applications, several technical specifications must be considered to ensure experimental success:

• Antibody Type: Both monoclonal and polyclonal HK3 antibodies are commercially available, each with distinct advantages. Monoclonal antibodies (like 67803-1-Ig) offer high specificity for a single epitope, while polyclonal antibodies (like 13333-1-AP) recognize multiple epitopes, potentially providing higher sensitivity .

• Validated Applications: Verify that the antibody has been validated for your specific application. Current data shows HK3 antibodies are validated for:

  • Western Blot (WB): Typical dilutions range from 1:5000-1:50000

  • Immunohistochemistry (IHC): Typical dilutions range from 1:20-1:2000

  • ELISA: Various formats available

  • Immunofluorescence (IF) and Immunocytochemistry (ICC)

• Species Reactivity: Most commercially available HK3 antibodies react with human, mouse, and rat samples, with some also demonstrating reactivity with pig samples .

• Molecular Weight Recognition: Confirm the antibody detects the correct molecular weight (99 kDa for full-length HK3) .

• Cross-Reactivity Assessment: Some antibodies (like EPR29196-29) have been specifically tested to not cross-react with related hexokinases (HK1, HK2, and HKDC1) .

What are the optimal protocols for detecting HK3 using immunohistochemistry in different tissue types?

Tissue-specific optimization is critical for successful HK3 detection by IHC:

For most tissue types, particularly lung cancer tissue, the following protocol has been validated:

• Sample Preparation: Use formalin-fixed, paraffin-embedded (FFPE) tissue sections at 4-6 μm thickness.

• Antigen Retrieval: Two methods have proven effective:

  • Primary Method: TE buffer pH 9.0 at 95-100°C for 15-20 minutes

  • Alternative Method: Citrate buffer pH 6.0 at 95-100°C for 15-20 minutes

• Antibody Incubation:

  • For polyclonal antibodies: Use 1:20-1:200 dilution (e.g., 13333-1-AP)

  • For monoclonal antibodies: Use 1:500-1:2000 dilution (e.g., 67803-1-Ig)

  • Optimal incubation conditions: 30-60 minutes at room temperature or overnight at 4°C

• Detection System: For most applications, a polymer-based detection system like Leica DS9800 (Bond™ Polymer Refine Detection) has demonstrated good results .

• Positive Control Tissue Selection: Human lung cancer tissue shows reliable positive staining for HK3, particularly in immune cells .

• Visualization: HK3 staining is typically observed in the cytoplasm, with particularly strong expression in immune cells within tissue samples .

Researchers should note that optimization may be required based on specific tissue types and fixation conditions. Expression levels vary significantly between tissue types, with notably low expression in brain and skeletal muscle samples .

How does HK3 expression correlate with immune infiltration in non-small cell lung cancer (NSCLC), and what methodologies best characterize this relationship?

HK3 expression shows significant correlation with immune infiltration in NSCLC, suggesting its potential role as a biomarker for immunotherapy response. Research findings demonstrate:

• Correlation with Immune Infiltration Metrics:
  HK3 expression shows positive correlation with:

  • Stromal score (r > 0.45, p < 0.05)

  • Immune score (r > 0.45, p < 0.05)

  • ESTIMATE score (r > 0.45, p < 0.05)

  • Negative correlation with tumor purity (p < 0.05)

• Immune Cell Population Associations:
  HK3 expression correlates particularly with:

  • T cells

  • Myeloid dendritic cells

  • NK cells

  • Monocytic lineage cells

• Methodological Approaches for Analysis:

  • Transcriptomic Correlation Analysis: Using TIMER or microenvironment cell populations-counter method to analyze RNAseq data from TCGA database

  • Gene Set Enrichment Analysis (GSEA): To identify biological functions associated with HK3 expression

  • Gene Set Variation Analysis (GSVA): To verify relationships between HK3 and immune functions

  • Immunohistochemistry: To validate HK3 and immune marker (CD8A, CD274) expression at the protein level

• Clinical Relevance:

  • Patients with high HK3 expression in LUSC had better survival outcomes

  • HK3 expression showed a 333.13-fold change in patients responding to PD-1 inhibitor therapy (PR group) compared to non-responders (PD group)

For researchers investigating this relationship, a multi-modal approach combining transcriptomic analysis with protein-level validation is recommended. RQ-PCR has proven effective for quantifying HK3 expression in clinical samples to predict immunotherapy response .

What is the role of HK3 in neutrophil differentiation, and how can antibody-based techniques verify PU.1-mediated regulation in acute promyelocytic leukemia?

Research has established HK3 as a critical link between glycolytic metabolism and neutrophil differentiation in acute promyelocytic leukemia (APL):

• Transcriptional Regulation Pathway:

  • PU.1 directly activates HK3 transcription

  • PML-RARA fusion protein (characteristic of APL) represses HK3 expression

  • This repression is reversed during APL differentiation therapy

• Experimental Verification Methods:

  A. Promoter Analysis:

  • HK3 promoter reporter assay using pGL4.10-basic luciferase vector

  • Cold Fusion cloning from genomic DNA

  • Transfection and luciferase activity measurement in H1299 cells

  • Results demonstrated PU.1 activation of the HK3 promoter, which was attenuated by PML-RARA

  B. Expression Analysis in Primary Samples:

  • Quantitative RT-PCR using TaqMan Gene Expression Assays (Hs00157923_m1 for HK3)

  • Analysis of 165 primary AML patient samples, 4 CD34+ progenitor cells, and 22 granulocytes

  • Results showed significantly lower HK3 expression in APL t(15;17) patients compared to non-APL samples and granulocytes (p < 0.0001)

  C. Functional Validation:

  • HK3 inhibition in APL cell lines

  • Assessment of neutrophil differentiation markers

  • Cell viability analysis

  • Results indicated reduced differentiation and viability when HK3 was inhibited

• Antibody Applications for Validation:

  • Western blot to detect HK3 protein expression changes during differentiation

  • Immunohistochemistry to assess HK3 expression in bone marrow biopsies

  • Chromatin immunoprecipitation (ChIP) to verify PU.1 binding to the HK3 promoter

These findings suggest HK3 antibodies are valuable tools for studying the metabolic regulation of hematopoietic differentiation, particularly in the context of acute leukemias.

How does HK3-mediated O-GlcNAcylation affect PD-L1 expression, and what antibody-based experimental approaches can elucidate this mechanism?

Recent research has identified a novel mechanism linking HK3 to tumor immune evasion through post-translational modification of the EP300 protein:

• Mechanistic Pathway:

  • HK3 maintains EP300 protein stability by regulating O-GlcNAcylation levels in clear cell renal cell carcinoma (ccRCC)

  • Site-specific O-GlcNAcylation of EP300 at Ser900 enhances its stability

  • EP300 regulates PD-L1 at both transcriptional and protein levels

  • Inhibition of HK3 reduces PD-L1 expression and restores T-cell cytotoxicity

• Experimental Design for Mechanism Validation:

  A. Protein Interaction Studies:

  • Co-immunoprecipitation using HK3 antibodies to detect interaction with EP300

  • Western blot analysis of O-GlcNAcylation levels using O-GlcNAc-specific antibodies

  • Site-directed mutagenesis of EP300 Ser900 to verify the specific site of modification

  B. Functional Studies:

  • HK3 knockdown or inhibition in ccRCC cells

  • Assessment of EP300 stability and PD-L1 expression

  • T-cell co-culture cytotoxicity assays

  • In vivo validation in immunocompetent mouse models

  C. Metabolic Analysis:

  • Measurement of UDP-GlcNAc levels as substrate for O-GlcNAcylation

  • Analysis of glycolytic flux in relation to O-GlcNAcylation activity

  • Effect of IL-10 from M2 tumor-associated macrophages (TAMs) on HK3 expression

• Translational Relevance:

  • HK3 inhibition as a potential strategy to enhance immune checkpoint blockade therapy

  • Combined targeting of glycolysis and immune checkpoints

  • Biomarker potential for predicting immunotherapy response

This research area represents a frontier in understanding metabolic-immune interactions in cancer, with significant implications for improving immunotherapy efficacy.

What are the common challenges in detecting low-abundance HK3 in tissue samples, and how can these be addressed?

Detecting HK3 can be challenging in certain tissues due to variable expression levels and technical factors:

• Tissue-Specific Expression Challenges:

  • Low HK3 expression has been documented in brain and skeletal muscle tissues

  • Higher expression typically observed in immune cells, lung tissue, and certain cancer types

• Sample Preparation Optimization:

  A. Antigen Retrieval Refinement:

  • For tissues with low HK3 expression, extended antigen retrieval may be necessary

  • TE buffer pH 9.0 has shown superior results compared to citrate buffer pH 6.0 for low-abundance detection

  • Optimization of retrieval time (15-25 minutes) and temperature (95-100°C) may be required

  B. Signal Amplification Strategies:

  • Use of polymer-based detection systems with higher sensitivity

  • Tyramide signal amplification for IHC/IF applications

  • Extended antibody incubation times (overnight at 4°C) for low-abundance targets

• Antibody Selection Considerations:

  • For low-abundance detection, polyclonal antibodies may offer greater sensitivity through recognition of multiple epitopes

  • Higher antibody concentrations may be required (1:20 dilution for IHC)

  • Validation with multiple antibodies targeting different epitopes can confirm specificity

• Controls and Validation:

  • Use of positive control tissues with known high HK3 expression (lung cancer tissue, THP-1 cells)

  • Inclusion of negative controls (tissues with HK3 knockdown)

  • Western blot validation prior to IHC to confirm antibody specificity and expected molecular weight (99 kDa)

• Common Artifacts and Solutions:

  • Background staining: More extensive blocking (5% NFDM/TBST) and longer wash steps

  • False positives: Verification with secondary-only controls

  • Degradation products: Fresh samples and inclusion of protease inhibitors during processing

By systematically optimizing these parameters, researchers can improve detection of low-abundance HK3 in challenging tissue types.

How might HK3 antibodies contribute to understanding SARS-CoV-2 variant-specific immune responses and antibody development?

The study of HK3.1 variant in SARS-CoV-2 research has opened interesting avenues for antibody development and neutralization studies:

• SARS-CoV-2 Variant Neutralization:

  • HK.3.1 has been identified as a SARS-CoV-2 variant requiring study in antibody neutralization assays

  • BD55-1205 antibody maintained neutralizing activity against multiple variants including HK.3.1

• Methodological Approaches for Variant-Specific Studies:

  A. Pseudovirus Neutralization Assays:

  • Generation of pseudotyped viruses expressing HK.3.1 spike protein

  • Titration of antibody concentrations to determine neutralization potency

  • Comparison across multiple variants to assess breadth of neutralization

  B. Structure-Function Analyses:

  • Crystal structure determination of antibody-RBD complexes

  • Analysis of binding footprints on receptor binding domain (RBD)

  • Identification of key residues mediating neutralization resistance

  C. Antibody Engineering Approaches:

  • Site-directed mutagenesis to enhance binding affinity

  • Assessment of somatic hypermutation (SHM) contributions to neutralization breadth

  • Testing germline-reverted variants to understand affinity maturation requirements

• Translation to Therapeutic Applications:

  • mRNA delivery of antibody genes showing high serum antibody titers in mouse models

  • Production and purification methodologies for therapeutic-grade antibodies

  • Combination approaches targeting multiple epitopes to prevent escape

The cross-disciplinary nature of this research demonstrates how antibody technologies developed for one field (glycolysis/cancer) can inform approaches in infectious disease research, particularly in understanding the evolving landscape of variant-specific immune responses.